Inovio Pharmaceuticals Reports Update on Ongoing Glioblastoma Study

Inovio Pharmaceuticals has announced an update on its clinical study for glioblastoma, a highly aggressive brain cancer. The study evaluates the safety, immunogenicity, and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab, radiation, and chemotherapy in patients with newly-diagnosed glioblastoma. The trial began on May 31, 2018, and the last update was submitted on July 2, 2025. The results of this study could influence Inovio's stock performance and investor sentiment.